Arcutis biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Westlake village, calif., march 05, 2025 (globe newswire) -- arcutis biotherapeutics, inc.  (nasdaq: arqt), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of arcutis' common stock to three newly hired employees. these awards were approved by the compensation committee of arcutis' board of directors and granted under the arcutis biotherapeutics, inc. 2022 inducement plan, with a grant date of march 3, 2025, as an inducement material to the new employees entering into employment with arcutis, in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking